Korro Bio, Inc. (KRRO) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$20.11M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$20.44M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$19.24M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$27.20M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$20.11M | (m) | (m) | (m) | $37.00K* | -$16.99M* | (m) | $13.59M | (m) | $108.00K |
| 2026-03-31 | Reported | (m) | -$20.44M | (m) | (m) | (m) | $21.00K | -$16.07M | (m) | $12.95M | (m) | $95.00K |
| 2025-09-30 | Reported | (m) | -$19.24M | (m) | (m) | (m) | $175.00K* | -$17.18M* | (m) | $13.82M | (m) | $0.00 |
| 2025-06-30 | Reported | (m) | -$27.20M | (m) | (m) | (m) | $140.00K* | -$19.23M* | (m) | $20.14M | (m) | $1.00K |
| 2025-03-31 | Reported | (m) | -$25.02M | (m) | (m) | (m) | $119.00K | -$24.45M | (m) | $19.74M | (m) | $0.00 |
| 2024-09-30 | Reported | (m) | -$23.29M | (m) | (m) | (m) | $4.88M* | -$16.09M* | (m) | $15.96M | (m) | -$9.00K |
| 2024-06-30 | Reported | (m) | -$24.13M | (m) | (m) | (m) | $5.96M* | -$14.59M* | (m) | $17.14M | (m) | $30.00K |
| 2024-03-31 | Reported | (m) | -$21.45M | (m) | (m) | (m) | $5.61M | -$21.89M | (m) | $13.57M | (m) | $17.00K |
| 2023-09-30 | Reported | (m) | -$19.15M | (m) | (m) | (m) | $246.00K* | -$11.77M* | (m) | $14.01M | (m) | $0.00 |
| 2023-06-30 | Reported | (m) | -$18.41M | (m) | (m) | (m) | $4.42M* | -$14.71M* | (m) | $13.13M | (m) | $27.00K |
| 2023-03-31 | Reported | (m) | -$20.09M | (m) | (m) | (m) | $1.51M | -$19.69M | (m) | $14.69M | (m) | $0.00 |
| 2022-09-30 | Reported | (m) | -$20.27M | (m) | $0.00 | (m) | -$16.00K* | -$11.80M* | (m) | $11.71M | (m) | -$23.00K |
| 2022-06-30 | Reported | (m) | -$21.27M | (m) | $0.00 | (m) | $4.00K* | -$13.48M* | (m) | $13.27M | (m) | $2.00K |
| 2022-03-31 | Reported | (m) | -$23.26M | (m) | $0.00 | (m) | $12.00K | -$17.34M | (m) | $13.78M | (m) | $12.00K |
| 2021-09-30 | Reported | (m) | -$24.99M | (m) | $0.00 | (m) | $311.00K* | -$15.02M* | (m) | $15.66M | (m) | $3.00K |
| 2021-06-30 | Reported | (m) | -$17.48M | (m) | $9.42M | (m) | $2.00M* | -$17.67M* | (m) | $17.40M | (m) | $10.00K |
| 2021-03-31 | Reported | (m) | -$20.20M | (m) | $4.65M | (m) | $543.00K | -$25.47M | (m) | $15.11M | (m) | $0.00 |
| 2020-09-30 | Reported | (m) | -$5.42M | (m) | $11.25M | (m) | $1.00M* | -$10.73M* | (m) | $10.15M | (m) | $15.00K |
| 2020-06-30 | Reported | (m) | -$6.20M | (m) | $8.52M | (m) | $909.00K* | -$10.26M* | (m) | $8.76M | (m) | $7.00K |
| 2020-03-31 | Reported | (m) | -$5.66M | (m) | $7.26M | (m) | $343.00K | -$9.36M | (m) | $6.67M | (m) | $38.00K |
| 2019-09-30 | Reported | (m) | -$1.25M | (m) | $24.24M | (m) | $155.00K* | $74.58M* | (m) | $5.22M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$7.02M | (m) | (m) | (m) | $29.00K* | -$4.47M* | (m) | $3.92M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$5.92M | (m) | (m) | (m) | $459.00K | -$6.15M | (m) | $3.45M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$5.06M | (m) | (m) | (m) | (m) | (m) | (m) | $3.55M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$121.86M | (m) | (m) | (m) | $518.00K | -$78.56M | (m) | $65.58M | (m) | $637.00K |
| 2024-12-31 | Reported | (m) | -$91.91M | (m) | (m) | (m) | $17.90M | -$60.07M | (m) | $63.64M | (m) | $141.00K |
| 2023-12-31 | Reported | (m) | -$84.53M | (m) | (m) | (m) | $7.84M | -$67.28M | (m) | $57.25M | (m) | $27.00K |
| 2022-12-31 | Reported | (m) | -$59.00M | (m) | $0.00 | (m) | $5.14M | -$53.65M | (m) | $42.20M | (m) | $10.00K |
| 2021-12-31 | Reported | (m) | -$84.03M | (m) | $14.07M | (m) | $2.91M | -$76.06M | (m) | $60.92M | (m) | $15.00K |
| 2020-12-31 | Reported | (m) | -$27.55M | (m) | $36.98M | (m) | $6.67M | -$45.19M | (m) | $37.41M | (m) | $35.00K |
| 2019-12-31 | Reported | (m) | -$20.68M | (m) | $28.95M | (m) | $1.06M | $34.22M | (m) | $18.78M | (m) | $0.00 |
| 2018-12-31 | Reported | (m) | -$18.94M | (m) | (m) | (m) | $436.00K | -$17.02M | (m) | $11.88M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$16.31M | (m) | (m) | (m) | $1.86M | -$14.61M | (m) | $11.97M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |